Ozempic Weight Loss Results: Clinical Data & Genetic Factors

Last reviewed: June 1, 2026

Last updated: June 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic (semaglutide) produces highly variable weight loss across individuals, with clinical trial data showing weight reductions ranging from 3% to 10% of body weight depending on baseline factors and adherence. Understanding what drives these differences can support a more realistic treatment discussion with your provider.

Weight loss outcomes depend on multiple factors beyond the medication alone: baseline metabolic health, genetic predispositions in GLP-1 signaling pathways, adherence patterns, and lifestyle integration. PlexusDx takes a precision-wellness approach by helping patients understand their individual context before and during treatment decisions.

Clinical Trial Data: What Real-World Weight Loss Looks Like

Landmark SUSTAIN trials evaluated semaglutide efficacy across 2–3 years. At the highest approved dose, participants achieved approximately 10% body weight reduction on average, though individual results ranged from minimal loss to 15% or greater.

Baseline body mass index (BMI) and starting weight significantly influenced outcomes. Patients with BMI >35 often saw larger percentage reductions, while those with BMI 27–30 experienced more modest results. These variations highlight why population averages may not predict individual response.

Individual Response Variation: Biomarkers and Genetic Context

Not all GLP-1 medications work equally across all people. Differences in genetic variants affecting GLP-1 receptor (GLP1R) and glucose-dependent insulinotropic peptide receptor (GIPR) signaling may influence appetite suppression magnitude and metabolic effects, though genetic predisposition does not determine exact medication response.

Additional biomarkers—including insulin resistance patterns, baseline glucose control, and inflammatory markers—provide clinical context for how a patient's metabolic system may respond to GLP-1 therapy. These factors work alongside genetic variation to shape overall outcomes.

Factor	Clinical Relevance to Weight Loss Response
GLP1R Genetic Variants	May influence appetite-suppression intensity and satiety signaling; variants like rs6923761 are mapped by Precision Peptide testing
GIPR Pathway Variants	Associated with glucose metabolism and incretin response; rs1800437 variant may affect dual-pathway medications (tirzepatide)
Baseline Insulin Resistance	Higher HOMA-IR scores may correlate with greater early weight loss due to improved metabolic efficiency
Inflammatory Markers	Elevated CRP or IL-6 may be associated with metabolic dysfunction; GLP-1 therapy may reduce inflammation alongside weight loss

Timeline Expectations: When Weight Loss Plateaus and Stabilizes

Most GLP-1 weight loss occurs within the first 3–6 months as dose escalation proceeds and appetite suppression peaks. After reaching the maintenance dose, weight loss often slows significantly, then stabilizes over 12–24 months, reflecting a new metabolic equilibrium.

Sustained weight loss requires consistent adherence and lifestyle support. Patients who maintain dietary and activity changes alongside medication typically preserve weight loss longer than those who rely on medication alone. Provider support and realistic goal-setting improve long-term outcomes.

Who Is Most Likely to Achieve Meaningful Weight Loss: Eligibility and Provider Assessment

GLP-1 medications are most clearly indicated for individuals with BMI ≥27 and weight-related comorbidities (hypertension, prediabetes, PCOS) or BMI ≥30 regardless of comorbidity. Patients with type 2 diabetes benefit from both weight loss and glycemic control. Eligibility requires comprehensive medical evaluation by a qualified provider.

Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and severe gastroparesis. A provider-led assessment should address medication interactions, renal function, and psychiatric medication stability. This evaluation ensures safety and identifies candidates most likely to benefit.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test maps predispositions in key GLP-1 pathway variants (GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, MC4R rs17782313) that may help provide context for how your metabolic system responds to GLP-1 therapy. These results should be interpreted alongside clinical biomarkers by a qualified healthcare provider to support a more personalized treatment conversation.

The genetic test does not predict exact medication response or guarantee weight loss outcomes—genetics represents one layer of the personalization puzzle. Combined with baseline metabolic markers, lifestyle readiness, and medical history, genetic insight can help patients and providers align treatment selection with individual predisposition patterns.

Understanding your genetic and biomarker context supports a more informed dialogue about medication choice, dosing strategy, and realistic timelines. PlexusDx compounded GLP-1 options (semaglutide injection, oral semaglutide, tirzepatide injection, or dual-compound GLP-Squared) can be tailored based on this personalized assessment, providing a precision-wellness approach to weight management treatment.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $229-$309/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.